Bladder Cancer
Prostate Cancer
EAU Edu Platform on Kidney Cancer
Home
Articles
Article of the Month
Editorials
Videos
Webcasts
Education
E-courses
Webinars
Online curriculum
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorials
Videos
Webcasts
Education
Terug
E-courses
Webinars
Online curriculum
Guidelines
Events
Upcoming event
17th European Multidisciplinary Congress on Urological Cancer
Home
/
KEYNOTE-426 study
Back
KEYNOTE-426 study
2023-06-03
Dr. Rini elaborates on the results of the KEYNOTE-426 study: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced ccRCC.
Share:
Previous
Next
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More
